Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295243 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00295243: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00295243 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00295243, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Participants will take GW572016 by mouth daily each cycle (cycles 28 days in length) and will be given Topotecan intravenously on Days 1, 8 and 15.
Interventions
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295243
The ClinicalTrials.gov registry entry for NCT00295243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topotecan is the first listed.
NCT00295243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295243 about?
NCT00295243 is a clinical study titled "Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies". Participants will take GW572016 by mouth daily each cycle (cycles 28 days in length) and will be given Topotecan intravenously on Days 1, 8 and 15.
What is the current status of trial NCT00295243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2004-09. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00295243?
The interventions under investigation include: Topotecan (DRUG).
Who is sponsoring clinical trial NCT00295243?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.